PD-L1 TPS is simple in theory—but far more complex in practice. When eligibility for life-changing immunotherapy hinges on a 1% or 50% score, even a 5% margin of error can shift a patient’s path entirely.

This 45-minute live webinar takes you inside the real-world diagnostic pressure points of PD-L1 TPS testing in NSCLC. With insights drawn from clinical research, pathology practice, and oncology decision-making, we examine the human limits of PD-L1 scoring and how AI can sharpen clinical decisions.

What you’ll learn:

• The 1% that changes everything
  Understand how small differences in PD-L1 Tumor Proportion Score (TPS) drastically influence therapy eligibility—and why that’s a clinical pain point.
• Cut-offs, callouts, and clinical consequences
  Explore why the 1% and 50% cut-offs carry outsized impact, and how subtle inconsistencies in interpretation can create major therapeutic divergence.
• The human factor: why pathologists disagree
  Dive into the technical, visual, and psychological reasons manual scoring is prone to variability—especially in borderline cases.
• Under-called. Over-called. Mis-called.
  See how PD-L1 is commonly misestimated in either direction, and how this leads to patient under-treatment or over-treatment.
• AI to the assist: can algorithms outscore the experts?
  Unpack the evidence on how AI is being trained to assist PD-L1 scoring—offering reproducibility, speed, and support in tough calls.
• Bridging the diagnostic divide
  Hear how pathologists and oncologists view PD-L1 differently—and how AI and digital tools may help unify decision-making.

Who should attend?

• Pathologists involved in biomarker testing
• Oncologists relying on PD-L1 scores for treatment planning
• Anyone involved in lung cancer diagnostics or therapeutic decision-making